In vitro and in vivo Assessment of Silver Nanoparticles Against Clostridium botulinum Type A Botulinum

Author(s): Mohammad Aminianfar , Siavash Parvardeh , Mohsen Soleimani* .

Journal Name: Current Drug Discovery Technologies

Volume 16 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Background: Clostridium botulinum causes botulism, a serious paralytic illness that results from the ingestion of a botulinum toxin. Because silver nanoparticle products exhibit strong antimicrobial activity, applications for silver nanoparticles in healthcare have expanded. Therefore, the objective of the current study was to assess a therapeutic strategy for the treatment of botulism toxicity using silver nanoparticles.

Methods: A preliminary test was conducted using doses that produce illness in laboratory animals to determine the absolute lethal dose (LD100) of botulinum toxin type A (BoNT/A) in mice. Next, the test animals were divided into six groups containing six mice each. Groups I, II and III were the negative control (botulinum toxin only), positive control-1 (nano-silver only) and positive control-2 (no treatment), respectively. The remaining groups were allocated to the toxin that was supplemented with three nano-silver treatments.

Results: The mortality rates of mice caused by BoNT/A significantly reduced in the treatment groups with different doses and injection intervals of nano-silver when compared to the negative control group. BoNT/A toxicity induced by intraperitoneal injection of the toxin of Clostridium botulinum causes rapid death while when coupled with nano-osilver results in delayed death in mice.

Conclusion: These results, while open to future improvement, represent a preliminary step towards the satisfactory control of BoNT/A with the use of silver nanoparticles for human protection against this bioterrorism threat. Further study in this area can elucidate the underlying mechanism for detoxifying BoNT/A by silver nanoparticles.

Keywords: Antibacterial, Clostridium botulinum, botulism, BoNT/A toxin, intoxication, nano-silver.

Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: Genetic, structural and mechanistic insights. Nat Rev Microbiol 2014; 12: 535-49.
Rust A, Leese C, Binz T, Davletov B. Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells. Oncotarget 2016; 7: 33220-8.
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol Rev 2017; 69: 200-35.
Deitiker P, Oshima M, Jankovic J, Atassi MZ. Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett 2017; 190: 257-64.
Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001; 285: 1059-70.
Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: A metabolic and cellular perspective. Toxicon 2001; 39: 1703-22.
Bhardwaj T, Somvanshi P. Pan-genome analysis of Clostridium botulinum reveals unique targets for drug development. Gene 2017; 623: 48-62.
Tsai YC, Maditz R, Kuo CL, et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA 2010; 107: 16554-9.
Kvitek L, Panáček A, Soukupova J, et al. Effect of surfactants and polymers on stability and antibacterial activity of Silver Nanoparticles (NPs). J Phys Chem 2008; 112: 5825-34.
Chen X, Schluesener HJ. Nanosilver: A nanoproduct in medical application. Toxicol Lett 2008; 176: 1-12.
Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009; 27: 76-83.
Xie P, Ji W, Wei Z. Preparation and properties of silver nanoparticlesCharacter Appl Nanomater 1: 40-8
El-Naggar NEA, Hussein MH, El-Sawah AA. Bio-fabrication of silver nanoparticles by phycocyanin, characterization, in vitro anticancer activity against breast cancer cell line and in vivo cytotoxicity. Sci Rep 2017; 7: 10844.
Goudarzi M, Mir N, Mousavi-Kamazani M, Bagheri S. Salavati-Niasari. Biosynthesis and characterization of silver nanoparticles prepared from two novel natural precursors by facile thermal decomposition methods. Sci Rep 2016; 6: 32539.
Kora AJ, Sashidhar RB. Antibacterial activity of biogenic silver nanoparticles synthesized with gum ghatti and gum olibanum: A comparative study. J Antibiot 2015; 68: 88-97.
Tareq FK, Fayzunnesa M, Kabir MS, Nuzat M. Mechanism of bio molecule stabilized selenium nanoparticles against oxidation process and Clostridium botulinum. Microb Pathog 2018 in press
Ema M, Okuda H, Gamo M, Honda K. A review of reproductive and developmental toxicity of silver nanoparticles in laboratory animals. Reprod Toxicol 2017; 67: 149-64.
Yoon KY, Byeon JH, Park JH, Hwang J. Susceptibility constants of Escherichia coli and Bacillus subtilis to silver and copper nanoparticles. Sci Total Environ 2007; 373: 572-5.
Feng QL, Wu J, Chen GQ, Cui FZ, Kim TN, Kim JO. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 2000; 52: 662-8.
Raffi M, Hussain F, Bhatti TM, Akhter JI, Hameed A, Hasan MM. Antibacterial characterization of silver nanoparticles against E. coli ATCC-15224. J Mater Sci Technol 2008; 24: 192-6.
Kim JS. Antibacterial activity of Ag+ ion-containing silver nanoparticles prepared using the alcohol reduction method. J Ind Eng Chem 2007; 13: 718-22.
Popoff MR. Botulinum neurotoxins: Still a privilege of clostridia? Cell Host Microbe 2018; 23: 145-6.
Chellapandi P, Prisilla A. Clostridium botulinum type A-virulome-gut interactions: A systems biology insight. Human Microb J 2018 in press
Willis B, Eubanks LM, Dickerson TJ, Janda KD. The strange case of the botulinum neurotoxin: Using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed 2008; 47: 8360-79.
Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: A model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther 2011; 338: 503-17.
Harris TL, Lowery CA, Hixon MS, Janda KD. A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity. ACS Chem Neurosci 2014; 5: 632-6.
Tsai YC, Kotiya A, Kiris E, et al. Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci USA 2017; 114: E5158-66.
Jacobson AR, Adler M, Silvaggi NR, et al. Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A. Toxicon 2017; 137: 36-47.
National Committee for Clinical Laboratory Standards. 2002.Reference method for broth dilution testing of yeast approved standard 22nd ed, Wayne, Pa: National committee for clinical laboratory standards 2002 NCCLS M27-A2.
Sharma SK, Ramzan MA, Singh BR. Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 2003; 41: 321-31.
Balali-Mood M, Moshiri M, Etemad L. Medical aspects of bio-terrorism. Toxicon 2013; 69: 131-42.
Vazquez-Cintron EJ, Ichtchenko K, Band PA. 2016. . Treatment methods using atoxic neurotoxin derivatives. US 20160296608A1 Patents.
Kumar R, Kukreja RV, Cai S, Singh BR. Differential role of molten globule and protein folding in distinguishing unique features of botulinum neurotoxin. Biochim Biophys Acta 2014; 1844: 1145-52.
Li WR, Xie XB, Shi QS, Zeng HY, You-Sheng OY, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol 2010; 85: 1115-22.
Durán N, Durán M, de Jesus MB, Seabra AB, Fávaro WJ, Nakazato G. Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity. Nanomed-Nanotechnol 2016; 12: 789-99.
Arakawa H, Neault JF, Tajmir-Riahi HA. Silver (I) complexes with DNA and RNA studied by Fourier transform infrared spectroscopy and capillary electrophoresis. Biophys J 2001; 81: 1580-7.
Kudrinskiy AA, Ivanov AY, Kulakovskaya EV. The mode of action of silver and silver halides nanoparticles against Saccharomyces cerevisiae cells. J Nanopart 2014; p. 568635.
Khadka P, Haque M, Krishnamurthi VR, Niyonshuti I, Chen J, Wang Y. Quantitative investigations reveal new antimicrobial mechanism of silver nanoparticles and ion. Biophys 2018; 114(1): 3690a.
Lee Y, Kim H, Kim S, et al. The effects of silver and arsenic on antioxidant system in Lemna paucicostata: Different effects on glutathione system. Toxicol Environ Health Sci 2016; 8: 332-40.
Davies JR, Reesa J, Liu SM, Acharya KR. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains. J Struct Biol 2018; 202: 113-7.
Sahaya B, Colliou N, Zadeh M, et al. Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex. Vaccine 2018; 36: 155-64.
McClements DJ, Xiao H. Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles. NPJ Sci Food 2017; 1: 6.
Zaidi S, Misba L, Khan AU. Nano-therapeutics: A revolution in infection control in post antibiotic era. Nanomed- Nanotechnol. Biol Med 2017; 13: 2281-301.
Soni KS, Desale SS, Bronich TK. Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. J Control Release 2016; 240: 109-26.
Panacek A, Kvitek L, Smekalova M, et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat Nanotechnol 2018; 13: 65-71.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [113 - 119]
Pages: 7
DOI: 10.2174/1570163815666180403163946
Price: $58

Article Metrics

PDF: 26